Non-CYP metabolism. However, side effects such as nausea, anorexia and vomiting may be potentially porphyrinogenic through reduction in caloric intake.

Cisplatin is an inorganic complex that contains a platinum atom surrounded in a plane by 2 chloride atoms and 2 ammonia molecules in the cis position.

Cisplatin is a platinum-containing antineoplastic agent used in the treatment of cancer such as ovarial cancer, vescical cancer, testis tumours with metastases, cancers in the head/neck region, and lungcancer. It is administered as an intravenous injection or infusion. Common adverse reactions of cisplatin that can be confused with an acute porphyric attack are vomiting, and nausea. Side effects such as nausea, anorexia and vomiting may be potentially porphyrinogenic through reduction in caloric intake.

Cisplatin has a non-enzymatic metabolism. Excretion is mainly in the urine: up to about 50% of a dose has been reported to be excreted in urine over 5 days, and platinum may be detected in tissue for several months afterwards. The unbound fraction, which is more rapidly cleared, may be actively secreted by the renal tubules. Interactions with CYP metabolism of other drugs not observed. Not listed as CYP-inducer or inhibitor (Rendic 2002). Cisplatin did not exert a significant effect on the PXR-mediated induction of CYP3A4 (Harmsen, 2009). Cisplatin was without inhibitory effect on CYP3A4 (Baumhakel, 2001).

Used uneventfully by AIP man in the treatment of testicular cancer (Arbus, 1981).

No.